PBT, IMRT provide similar patient-reported outcomes for prostate cancer at 5 years
Data from the PARTIQoL trial show no significant difference in progression-free survival, bowel function, and other patient quality-of-life measures between PBT and IMRT.
Prior local therapy does not impact mCRPC survival with ARPI treatment
A late-breaking abstract at ASTRO 2024 shows local therapy history does not significantly affect the risk of death in patients with mCRPC receiving an ARPI.
How do prostate cancer treatments differ in longterm functional outcomes?
New CEASAR findings at ASTRO 2024 show how 3 treatment modalities differ in prostate cancer patient functioning—as well as how patients perceive the issues.
Targeting primary tumor, metastasized lesions linked to improved 5-year omHSPC survival
Ga-68 PSMA-11 tracer could guide SCINTIX radiation therapy for metastasized prostate cancer
Ga-68 PSMA-11 radiotracer may be a feasible option for SCINTIX radiation therapy in patients whose prostate cancer has spread to the bones.
Hypofractionated radiation therapy improves 10-year prostate cancer outcomes
Follow-up phase 3 analyses support a hypofractionated radiation therapy regimen to conventional dosing in patients with prostate cancer.